In Brief: Somatix GVAX
Executive Summary
Somatix GVAX: Phase I trials with the genetically-engineered GVAX cancer vaccine in patients with advanced malignant melanoma show the vaccine is well-tolerated and stimulates an immune response, clinical investigators report at the American Society of Clinical Oncologists May 22 in Los Angeles. Ten patients have received the full course of vaccinations of three vaccinations over two months, and three patients' disease has been stabilized for eight months or more. The vaccine is composed of a patient's own cells genetically modified with the gene for the immunostimulant GM-CSF, Somatix reports...